Arvest Bank Trust Division Sells 323 Shares of AbbVie Inc. $ABBV

Arvest Bank Trust Division decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 0.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 94,971 shares of the company’s stock after selling 323 shares during the quarter. AbbVie comprises about 1.0% of Arvest Bank Trust Division’s investment portfolio, making the stock its 28th biggest holding. Arvest Bank Trust Division’s holdings in AbbVie were worth $17,629,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of ABBV. Fiera Capital Corp raised its position in shares of AbbVie by 33.7% in the 2nd quarter. Fiera Capital Corp now owns 108,810 shares of the company’s stock worth $20,197,000 after purchasing an additional 27,419 shares during the last quarter. Investment Partners LTD. increased its stake in AbbVie by 0.6% during the 2nd quarter. Investment Partners LTD. now owns 17,304 shares of the company’s stock valued at $3,212,000 after purchasing an additional 111 shares in the last quarter. Avalon Trust Co raised its holdings in AbbVie by 20.6% in the second quarter. Avalon Trust Co now owns 3,272 shares of the company’s stock worth $607,000 after buying an additional 560 shares during the last quarter. Thompson Davis & CO. Inc. bought a new position in shares of AbbVie in the second quarter worth approximately $391,000. Finally, Capital Investment Counsel Inc grew its holdings in shares of AbbVie by 97.2% during the second quarter. Capital Investment Counsel Inc now owns 2,079 shares of the company’s stock valued at $386,000 after buying an additional 1,025 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ABBV. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $170.00 to $270.00 in a report on Wednesday, September 17th. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. JPMorgan Chase & Co. increased their price objective on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Hsbc Global Res downgraded AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Finally, HSBC set a $225.00 target price on shares of AbbVie in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $238.55.

AbbVie Stock Performance

NYSE:ABBV opened at $232.25 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The stock has a 50-day simple moving average of $224.49 and a two-hundred day simple moving average of $203.63. The firm has a market capitalization of $410.47 billion, a PE ratio of 110.60, a P/E/G ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.